Patient Organisation Profile
Tag
ms
-
-
Annual conference in multiple sclerosis: High-quality care for improved patient outcomes ECTRIMS FOCUSED WORKSHOP - „Advancing Trial Design in Progressive Multiple Sclerosis (in association with the Progressive MS Alliance)” 4th International Porto Congress of Multiple Sclerosis The 12th World Congress on Brain Injury
-
Report from Dr Madara Lazdane from Riga, Latvia visiting Department of Biomedical Science and Neuromotor - Clinical of Neurology, Bologna, Italy under the supervision of Prof. Pietro Cortelli
-
The new CME article February 2017: “Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?” is online now!
Please log-in and browse to the LEARN section on the EAN Website and answer the questions! All e-learning activities are free-of-charge… Continue Reading -
Latvia - officially the Republic of Latvia (Latvian: Latvijas Republika), is a beautiful country in the Baltic region of Northern Europe, one of the three Baltic states. The name “Latvia” comes from the ancient Latgalians, one of four Indo-European Baltic tribes who formed the core of modern Latvians. With a coastline of 531km along the Baltic Sea, Latvia is bordered by Estonia, Lithuania, Russia, and Belarus, and has 64,589 km2 of scenic plains and rivers, lakes and hills, including a majestic coastline.
-
Paper of the MonthFeatured Slider
Paper of the month: Improved prognosis of multiple sclerosis in the last 10 years
November 1, 2016For November 2016 we have selected: Cree BAC, Gourraud P-A, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016:80;499-510. Studies describing the natural history of multiple sclerosis (MS) before the availability of disease-modifying treatments have reported a progression of the disease from the relapsing-remitting form to the secondary progressive form in about 50% of patients at 19 years after the onset. -
ECTRIMS Annual Congress 2016 – London, UK, September 14-17
-
By Anna Sauerbier A successful MS fundraising story http://www.emsp.org/news-messages/2878/ What does quality care mean? http://www.eu-patient.eu/Members/Weekly-Mailing/quality-care-survey/ Countries start to act on non-communicable diseases but need to speed up efforts to meet global commitments http://www.who.int/mediacentre/news/notes/2016/noncommunicable-diseases-global-commitments/en/ Presenting a… Continue Reading
-
EAN / ECTRIMS agreement for collaboration signed
-
All e-learning activities are free-of-charge for EAN registered users.
Answer all questions correctly and you will receive one hour of CME. European Journal of Neurology
Every month one article is chosen for online learning. The following articles are available free… Continue Reading -
EAN Congress news
Copenhagen 2016: Report on Symposium 7 “Understanding functional connectivity using MRI”
May 31, 2016Symposium 07 – Understanding functional connectivity using MRI Hall M1, Tuesday, 31st of May, 08:00-10:00 Chairpersons L. Kappos, Basel/Switzerland M. Filippi, Milan/Italy Brain functional connectivity assessed using MRI: the basis
B. B. Biswal, Newark/USA Clinical applications in MS
M. A.… Continue Reading -
EAN Congress newsTop Articles
Neurological News from Denmark VII – the land of the 2nd EAN congress 2016: Basic Danish MS Research.
May 4, 2016By Trevor Owens Basic MS Research can be defined as analysis of mechanism of induction, pathogenesis and regulation of neuroinflammatory demyelinating disease using in vivo and in vitro experimental models. This is an area of longstanding and growing strength for… Continue Reading -
Paper of the MonthFeatured Slider
Paper of the month: Primary progressive multiple sclerosis still lacks effective treatment: no benefit from fingolimod.
April 1, 2016or April 2016 we have selected: Lublin F, Miller DH, Freedman MS, et al., on behalf of the INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomized, double-blind, placebo-controlled trial. Lancet Neurol, 27 Jan 2016; pii: S0140-6736(15)01314-8. doi: 10.1016/S0140-6736(15)01314-8. Primary progressive multiple sclerosis (PPMS) represents around 10-15% of the clinical forms of MS. Several characteristics differentiate PPMS from the relapse-onset MS, the classical more frequent form: older age at onset, equal prevalence between sexes, less inflammatory component at the MRI, and quicker progression of disability. -
Forum
Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri – Comment to EMA recommendation
March 1, 2016After more than a decade from the natalizumab approval, most MS specialists consider this biological therapy as one of the most efficient drugs that we have nowadays to treat relapsing-remitting MS patients. However, the problem we have to face when we start to use natalizumab is the risk of the occurrence of progressive multifocal leukoencephalopathy (PML) in some patients. -
Report from Maria Paola Cabboi from Italy visiting the Laboratory of Histology of the Neurology Clinic, University of Würzburg, Germany under the supervision of Professor Claudia Sommer I attended the Laboratory of Histology of the Neurology Clinic of the University… Continue Reading